Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1016/S1473-3099(20)30942-7

http://scihub22266oqcxt.onion/10.1016/S1473-3099(20)30942-7
suck pdf from google scholar
33485468!7825810!33485468
unlimited free pdf from europmc33485468    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid33485468      Lancet+Infect+Dis 2021 ; 21 (5): 637-646
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial #MMPMID33485468
  • Ella R; Vadrevu KM; Jogdand H; Prasad S; Reddy S; Sarangi V; Ganneru B; Sapkal G; Yadav P; Abraham P; Panda S; Gupta N; Reddy P; Verma S; Kumar Rai S; Singh C; Redkar SV; Gillurkar CS; Kushwaha JS; Mohapatra S; Rao V; Guleria R; Ella K; Bhargava B
  • Lancet Infect Dis 2021[May]; 21 (5): 637-646 PMID33485468show ga
  • BACKGROUND: To mitigate the effects of COVID-19, a vaccine is urgently needed. BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG) or alum (Algel). METHODS: We did a double-blind, multicentre, randomised, controlled phase 1 trial to assess the safety and immunogenicity of BBV152 at 11 hospitals across India. Healthy adults aged 18-55 years who were deemed healthy by the investigator were eligible. Individuals with positive SARS-CoV-2 nucleic acid and/or serology tests were excluded. Participants were randomly assigned to receive either one of three vaccine formulations (3 mug with Algel-IMDG, 6 mug with Algel-IMDG, or 6 mug with Algel) or an Algel only control vaccine group. Block randomisation was done with a web response platform. Participants and investigators were masked to treatment group allocation. Two intramuscular doses of vaccines were administered on day 0 (the day of randomisation) and day 14. Primary outcomes were solicited local and systemic reactogenicity events at 2 h and 7 days after vaccination and throughout the full study duration, including serious adverse events. Secondary outcome was seroconversion (at least four-fold increase from baseline) based on wild-type virus neutralisation. Cell-mediated responses were evaluated by intracellular staining and ELISpot. The trial is registered at ClinicalTrials.gov (NCT04471519). FINDINGS: Between July 13 and 30, 2020, 827 participants were screened, of whom 375 were enrolled. Among the enrolled participants, 100 each were randomly assigned to the three vaccine groups, and 75 were randomly assigned to the control group (Algel only). After both doses, solicited local and systemic adverse reactions were reported by 17 (17%; 95% CI 10.5-26.1) participants in the 3 mug with Algel-IMDG group, 21 (21%; 13.8-30.5) in the 6 mug with Algel-IMDG group, 14 (14%; 8.1-22.7) in the 6 mug with Algel group, and ten (10%; 6.9-23.6) in the Algel-only group. The most common solicited adverse events were injection site pain (17 [5%] of 375 participants), headache (13 [3%]), fatigue (11 [3%]), fever (nine [2%]), and nausea or vomiting (seven [2%]). All solicited adverse events were mild (43 [69%] of 62) or moderate (19 [31%]) and were more frequent after the first dose. One serious adverse event of viral pneumonitis was reported in the 6 mug with Algel group, unrelated to the vaccine. Seroconversion rates (%) were 87.9, 91.9, and 82.8 in the 3 mug with Algel-IMDG, 6 mug with Algel-IMDG, and 6 mug with Algel groups, respectively. CD4(+) and CD8(+) T-cell responses were detected in a subset of 16 participants from both Algel-IMDG groups. INTERPRETATION: BBV152 led to tolerable safety outcomes and enhanced immune responses. Both Algel-IMDG formulations were selected for phase 2 immunogenicity trials. Further efficacy trials are warranted. FUNDING: Bharat Biotech International.
  • |Adolescent[MESH]
  • |Adult[MESH]
  • |Antibodies, Neutralizing/blood[MESH]
  • |Antibodies, Viral/blood[MESH]
  • |COVID-19 Vaccines/adverse effects/*immunology[MESH]
  • |COVID-19/*prevention & control[MESH]
  • |Double-Blind Method[MESH]
  • |Female[MESH]
  • |Humans[MESH]
  • |Immunoglobulin G/blood[MESH]
  • |Male[MESH]
  • |Middle Aged[MESH]
  • |SARS-CoV-2/*immunology[MESH]
  • |Toll-Like Receptor 7/agonists[MESH]
  • |Toll-Like Receptor 8/agonists[MESH]
  • |Vaccination[MESH]
  • |Vaccines, Inactivated/immunology[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box